Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Canton Strategic Holdings, Inc. filings document the completed name change from Tharimmune, Inc. and ticker change from THAR to CNTN, along with the company's digital asset treasury strategy tied to Canton Coin and the Canton Network. The 8-K record covers material events, amended charter and bylaws, Regulation FD disclosures, full-year operating and financial results, and governance participation through the Canton Foundation.
Its filings also describe capital-structure matters, including registered offerings, at-the-market sales agreements, Form S-3 registration statements, common stock and pre-funded warrant issuance, and related material agreements. Governance disclosures address board composition, bylaws, shareholder matters, and the company's public reporting profile across digital asset treasury and clinical-stage research activities.
Canton Strategic Holdings, Inc. director Gary S. Stetz reported open-market sales of company Common Stock. He sold a total of 100,351 shares in multiple transactions on May 22, 2026 and May 26, 2026 at prices ranging from $3.40 to $3.47 per share. After these sales, he directly owns 134,175 shares of Canton Strategic Holdings Common Stock.
Canton Strategic Holdings, Inc. director Gary S. Stetz reported open-market sales of company Common Stock. He sold a total of 100,351 shares in multiple transactions on May 22, 2026 and May 26, 2026 at prices ranging from $3.40 to $3.47 per share. After these sales, he directly owns 134,175 shares of Canton Strategic Holdings Common Stock.
Canton Strategic Holdings reported a sharp increase in scale and a much larger loss for the quarter ended March 31, 2026, reflecting its pivot to a digital asset treasury strategy built around Canton Coin (CC). Total assets rose to $584.7 million, driven mainly by CC holdings with a fair value of $541.6 million and cash of $41.5 million.
The company posted a quarterly net loss of $47.3 million versus $2.5 million a year earlier, largely due to $36.9 million in operating expenses and a $15.0 million unrealized loss on CC. General and administrative costs surged to $36.6 million, including $32.3 million of stock-based compensation linked to its capital markets and strategic advisory arrangements.
To fund the new strategy, Canton raised substantial capital: a January 2026 registered direct offering plus at-the-market sales and warrant exercises generated about $87.0 million of financing cash inflows during the quarter, following more than $537 million of private placement proceeds in November 2025. Management believes existing liquidity can support operations through at least March 2027 while it runs both the CC-centric treasury segment and its legacy clinical-stage biotechnology programs.
Canton Strategic Holdings reported a sharp increase in scale and a much larger loss for the quarter ended March 31, 2026, reflecting its pivot to a digital asset treasury strategy built around Canton Coin (CC). Total assets rose to $584.7 million, driven mainly by CC holdings with a fair value of $541.6 million and cash of $41.5 million.
The company posted a quarterly net loss of $47.3 million versus $2.5 million a year earlier, largely due to $36.9 million in operating expenses and a $15.0 million unrealized loss on CC. General and administrative costs surged to $36.6 million, including $32.3 million of stock-based compensation linked to its capital markets and strategic advisory arrangements.
To fund the new strategy, Canton raised substantial capital: a January 2026 registered direct offering plus at-the-market sales and warrant exercises generated about $87.0 million of financing cash inflows during the quarter, following more than $537 million of private placement proceeds in November 2025. Management believes existing liquidity can support operations through at least March 2027 while it runs both the CC-centric treasury segment and its legacy clinical-stage biotechnology programs.
Canton Strategic Holdings, Inc. ownership update: a group of related LCV entities and principals report combined beneficial ownership tied to issued shares and exercisable warrants. The Reporting Persons collectively beneficially own 757,724 shares of Common Stock and are deemed to beneficially own 5,446,000 shares issuable upon exercise of warrants within 60 days, subject to contractual limits that cap ownership at 9.99% of outstanding shares. The percentage calculations use 56,656,271 shares outstanding as of March 31, 2026.
Canton Strategic Holdings, Inc. ownership update: a group of related LCV entities and principals report combined beneficial ownership tied to issued shares and exercisable warrants. The Reporting Persons collectively beneficially own 757,724 shares of Common Stock and are deemed to beneficially own 5,446,000 shares issuable upon exercise of warrants within 60 days, subject to contractual limits that cap ownership at 9.99% of outstanding shares. The percentage calculations use 56,656,271 shares outstanding as of March 31, 2026.
Canton Strategic Holdings, Inc. is undergoing a major shift from a traditional biotechnology business to a Canton Coin (CC)–focused digital asset treasury and Canton Network participation strategy. The company now prioritizes acquiring, holding and deploying CC, including validator operations and token management.
It still runs clinical-stage biotech programs such as GV104, a buccal nalmefene film for opioid exposure being advanced via the 505(b)(2) pathway, and GV023, an oral infliximab program licensed from Intract. Recent financings include a $545 million November 2025 PIPE and a $54.9 million January 2026 underwritten offering, plus an ATM program allowing up to $300 million of additional stock sales. Management and board changes in late 2025 and early 2026 align leadership with the new CC-centric strategy, which carries significant regulatory, market, custody and volatility risks that could materially affect results and the stock price.
Canton Strategic Holdings, Inc. is undergoing a major shift from a traditional biotechnology business to a Canton Coin (CC)–focused digital asset treasury and Canton Network participation strategy. The company now prioritizes acquiring, holding and deploying CC, including validator operations and token management.
It still runs clinical-stage biotech programs such as GV104, a buccal nalmefene film for opioid exposure being advanced via the 505(b)(2) pathway, and GV023, an oral infliximab program licensed from Intract. Recent financings include a $545 million November 2025 PIPE and a $54.9 million January 2026 underwritten offering, plus an ATM program allowing up to $300 million of additional stock sales. Management and board changes in late 2025 and early 2026 align leadership with the new CC-centric strategy, which carries significant regulatory, market, custody and volatility risks that could materially affect results and the stock price.
Canton Strategic Holdings reported its first full-year results since adopting a Canton Network–focused digital asset strategy. The company raised $545 million in a November 2025 private placement to build a large Canton Coin (CC) treasury and support its role on the Canton Network.
As of December 31, 2025, Canton Strategic held 3,339,569,946 CC with a fair value of $501,760,369 and had $17 million in cash, but has not recognized any revenue since inception. Operating expenses rose to $20.1 million in 2025 from $12.4 million in 2024, driven by the digital asset transition and $6 million of non-recurring compensation.
The company recorded an unrealized loss on digital assets of $22.0 million, contributing to a 2025 net loss of $35.9 million, or ($1.12) per diluted share, versus a $12.2 million loss, or ($9.41), in 2024. It reported an accumulated deficit of $72.8 million. Early 2026 steps included a $55 million underwritten equity offering, an at-the-market program, and approval to operate as a Super Validator on a network processing over one million daily transactions and more than $9 trillion in monthly volume.
Canton Strategic Holdings reported its first full-year results since adopting a Canton Network–focused digital asset strategy. The company raised $545 million in a November 2025 private placement to build a large Canton Coin (CC) treasury and support its role on the Canton Network.
As of December 31, 2025, Canton Strategic held 3,339,569,946 CC with a fair value of $501,760,369 and had $17 million in cash, but has not recognized any revenue since inception. Operating expenses rose to $20.1 million in 2025 from $12.4 million in 2024, driven by the digital asset transition and $6 million of non-recurring compensation.
The company recorded an unrealized loss on digital assets of $22.0 million, contributing to a 2025 net loss of $35.9 million, or ($1.12) per diluted share, versus a $12.2 million loss, or ($9.41), in 2024. It reported an accumulated deficit of $72.8 million. Early 2026 steps included a $55 million underwritten equity offering, an at-the-market program, and approval to operate as a Super Validator on a network processing over one million daily transactions and more than $9 trillion in monthly volume.
Canton Strategic Holdings, Inc. entered into an amended and restated at-the-market sales agreement with Clear Street LLC and Virtu Americas LLC to sell shares of its common stock from time to time. The agreement provides for an aggregate gross sales price of up to $300,000,000 of common stock, excluding shares previously sold under the prior agreement.
Sales will be made under the company’s effective Form S‑3 shelf registration and related prospectus supplement, through at-the-market transactions, negotiated deals or block trades, as permitted by law. The sales agents will use commercially reasonable efforts, earn commissions of up to 3.00% of gross proceeds, and either party can suspend or terminate the offering.
Canton Strategic Holdings, Inc. entered into an amended and restated at-the-market sales agreement with Clear Street LLC and Virtu Americas LLC to sell shares of its common stock from time to time. The agreement provides for an aggregate gross sales price of up to $300,000,000 of common stock, excluding shares previously sold under the prior agreement.
Sales will be made under the company’s effective Form S‑3 shelf registration and related prospectus supplement, through at-the-market transactions, negotiated deals or block trades, as permitted by law. The sales agents will use commercially reasonable efforts, earn commissions of up to 3.00% of gross proceeds, and either party can suspend or terminate the offering.
Canton Strategic Holdings, Inc. is registering an at-the-market offering to sell up to $300,000,000 of its common stock under an amended Sales Agreement with Clear Street LLC and Virtu Americas LLC, permitting sales from time to time through or to the Sales Agents.
The program amends an earlier ATM arrangement, follows prior issuances including a January registered offering and a November PIPE, and permits negotiated or Rule 415(a)(4) at-the-market sales with commissions up to 3.0% of gross proceeds; timing and amounts sold are subject to the Sales Agreement terms.
Canton Strategic Holdings, Inc. is registering an at-the-market offering to sell up to $300,000,000 of its common stock under an amended Sales Agreement with Clear Street LLC and Virtu Americas LLC, permitting sales from time to time through or to the Sales Agents.
The program amends an earlier ATM arrangement, follows prior issuances including a January registered offering and a November PIPE, and permits negotiated or Rule 415(a)(4) at-the-market sales with commissions up to 3.0% of gross proceeds; timing and amounts sold are subject to the Sales Agreement terms.
Canton Strategic Holdings, Inc. reported that its Chairman and Chief Executive Officer, Mark Wendland, has been elected to the Board of Directors of the Canton Foundation. This is described as underscoring the company’s leadership role in helping accelerate institutional adoption of the Canton Network.
The Canton Foundation is the independent governance body overseeing operation, standards, the validator framework, and policies related to the Global Synchronizer and broader Canton Network operations. With Wendland joining 17 existing Board members from major global financial institutions, Canton Strategic Holdings also becomes a Premier Member of the Foundation, deepening its alignment with the Foundation’s mission to support growth and governance of the Canton Network.
Canton Strategic Holdings, Inc. reported that its Chairman and Chief Executive Officer, Mark Wendland, has been elected to the Board of Directors of the Canton Foundation. This is described as underscoring the company’s leadership role in helping accelerate institutional adoption of the Canton Network.
The Canton Foundation is the independent governance body overseeing operation, standards, the validator framework, and policies related to the Global Synchronizer and broader Canton Network operations. With Wendland joining 17 existing Board members from major global financial institutions, Canton Strategic Holdings also becomes a Premier Member of the Foundation, deepening its alignment with the Foundation’s mission to support growth and governance of the Canton Network.
Canton Strategic Holdings, Inc., formerly Tharimmune, Inc., has completed a corporate rebrand to align with its digital asset treasury strategy focused on the Canton Network. The company changed its legal name and amended its charter and bylaws, and its NASDAQ ticker is moving from “THAR” to “CNTN” effective February 18, 2026.
The press release highlights that the company was established in November 2025 through a $545 million private placement and is pursuing value creation via Canton Coin acquisition, operating a Super Validator, and investing in applications that support institutional adoption of the Canton Network. Recent milestones include approval as a Super Validator, additions of institutional leaders such as former CFTC Commissioner Jill Sommers and DRW Chief of Staff William Wiley to the board, and closing a $55 million underwritten registered offering to fund further growth. The company also continues to operate clinical-stage biotech research and development alongside its digital asset activities.
Tharimmune, Inc. officer Angela Dominy Radkowski, the company’s Chief Operating Officer, filed an initial insider ownership report. As of the event date of 02/05/2026, she reports that no Tharimmune securities are beneficially owned. The filing is made solely by this one reporting person.